Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CETP | P11597 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11990041 | 1.00 | CETP (0.46) | CETPPKMTSHRLMNAHTT | |
| SCHEMBL9944456 | 1.00 | CETP (0.46) | CETPPKMTSHRLMNAHTT | |
| SCHEMBL21307401 | 0.76 | CETP (0.40) | CETPPKMTSHR | |
| SCHEMBL12218519 | 0.76 | CETP (0.40) | CETPPKMTSHR | |
| SCHEMBL10098406 | 0.76 | CETP (0.40) | CETPPKMTSHR | |
| SCHEMBL420845 | 0.75 | TSHR (0.53) | TSHR | |
| SCHEMBL13389339 | 0.75 | TSHR (0.53) | TSHR | |
| SCHEMBL421719 | 0.75 | TSHR (0.53) | TSHR | |
| SCHEMBL9319804 | 0.75 | CETP (0.50) | CETPPKMLMNAHTTKMT2A | |
| SCHEMBL25005646 | 0.74 | CETP (0.39) | CETPPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | NOVARTIS AG (CH) | 2024-02-27 | — | — | US | disclosed |
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | NOVARTIS AG (CH) | 2021-07-29 | — | — | US | disclosed |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | NOVARTIS AG (CH) | 2020-12-10 | — | — | US | disclosed |
| US-RE46757-E1 | Pyridine and pyrazine derivative for the treatment of CF | NOVARTIS AG (CH) | 2018-03-20 | — | — | US | disclosed |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | NOVARTIS AG (CH) | 2017-03-16 | — | — | US | disclosed |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | BAETTIG URS (GB) | 2014-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210228554-A1 | Pyridine and Pyrazine Derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CETP 3800/4885PKM 1348/4885TSHR 2129/4885 |
| US-20200383960-A1 | Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis | CFTR, OPRK1, CHRM3 | CETP 3662/4885PKM 1075/4885TSHR 1762/4885 |
| US-11911371-B2 | Pyridine and pyrazine derivative for the treatment of chronic bronchitis | CFTR, OPRK1, CHRM3 | CETP 4143/4885PKM 1219/4885TSHR 2138/4885 |
| US-20170071919-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CETP 3800/4885PKM 1348/4885TSHR 2129/4885 |
| US-20140135329-A1 | Pyridine and Pyrazine derivative for the Treatment of CF | CFTR, OPRK1, OPRD1 | CETP 3800/4885PKM 1348/4885TSHR 2129/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.